www.fdanews.com/articles/157281-defactinib-in-combination-with-weekly-paclitaxel-achieves-a-complete-response-in-platinum-resistant-ovarian-cancer
Defactinib in Combination With Weekly Paclitaxel Achieves a Complete Response in Platinum-Resistant Ovarian Cancer
July 23, 2013
Verastem has achieved positive results in a study of defactinib in platinum-resistant ovarian cancer patients.
Businesswire
Businesswire